Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$27.19M+381.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert N. Fried
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 117
- Beta
- 2.09
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.73
Financials
Revenue
$27.19M+381.9%Net Income
$-1.17MEBITDA
$-1.11MFree Cash Flow
$2.57MEPS (diluted)
$-0.01Shares Outstanding (diluted)
79.15M+108.8%Operating Expenses
$18.69MCash & Debt
$0.00Return of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $129.42M | $17.38M | $0.22 |
| 2024 | $99.60M | $8.55M | $0.11 |
| 2023 | $83.57M | $-4.94M | $-0.07 |
| 2022 | $72.05M | $-16.54M | $-0.24 |
| 2021 | $67.45M | $-27.13M | $-0.40 |
| 2020 | $59.26M | $-19.93M | $-0.33 |
| 2019 | $46.29M | $-32.15M | $-0.56 |
| 2018 | $31.56M | $-33.32M | $-0.61 |
| 2017 | $21.20M | $-11.38M | $-0.26 |
| 2016 | $21.66M | $-2.93M | $-0.08 |
| 2015 | $17.88M | $-2.77M | $-0.08 |
| 2014 | $15.31M | $-5.39M | $-0.15 |
| 2013 | $10.16M | $-4.42M | $-0.13 |
| 2012 | $11.61M | $-11.66M | $-0.39 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.32
- Implied price
- $9.35
- Return from $1.84
- 38.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.65 — today's price is already 60.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | 17.8% | 21.9% | 25.6% | 28.9% | 31.9% |
| 3.0% | 23.8% | 28.2% | 32.0% | 35.5% | 38.6% |
| 8.0% | 29.8% | 34.4% | 38.4% | 42.1% | 45.3% |
| 13.0% | 35.8% | 40.6% | 44.8% | 48.6% | 52.1% |
| 18.0% | 41.8% | 46.8% | 51.3% | 55.2% | 58.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60+0.00%Social Signal Score
Mentions (14)
- Newsbusinesswire.com·6d ago·Positive
Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Aging--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it will support the Sixth Annual Longevity Summit taking place from December 9 to 10, 2026, at the Buck Institute for Research on Aging in Novato, California. The …
View source ↗ - Newsbusinesswire.com·10d ago·Negative
Niagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ Plus LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has partnered with Truemed to provide qualified customers the option to purchase the Niagen™ At-Home Injection Kit using Health Savings Account (HS…
View source ↗ - Newsbusinesswire.com·13d ago·Neutral
Niagen Bioscience Announces Participation in Upcoming Investor Conferences LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: A.G.P. Virtual Consumer Showcase Virtual showcase offering consumer company management teams a platform to share their story with …
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Negative
Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates Niagen Bioscience (NAGE) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.
View source ↗ - Newsbusinesswire.com·18d ago·Neutral
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026. Third Quarter 2026 Financial and Business Highlights Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Direct to …
View source ↗ - Newsbusinesswire.com·31d ago·Positive
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen™ At-Home Injection Kit, featuring the Company's first ready-to-inject liquid formulation with Niagen™ …
View source ↗ - Newsbusinesswire.com·33d ago·Negative
…nce Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Beauty--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab. The inaugural produc…
View source ↗ - Newsbusinesswire.com·38d ago·Neutral
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2026. The company will…
View source ↗ - Newsbusinesswire.com·47d ago·Neutral
Niagen Bioscience to Present at LD Micro 20th Annual Main Event LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the 20th Annual LD Micro Main Event from Monday, October 19 to 21, 2026, in Los Angeles, CA. Niagen Bioscience Chief Executive Officer, Robert Fried, will present on Wednesday, …
View source ↗ - Newsbusinesswire.com·66d ago·Negative
…gages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BioPharma--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the adv…
View source ↗ - Newsbusinesswire.com·73d ago·Neutral
Niagen Bioscience to Present at Canaccord Genuity's Well Summit LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's Well Summit, taking place from September 28 to 30, 2026, in New York. Mr. Fried is scheduled t…
View source ↗ - Newsbusinesswire.com·81d ago·Positive
Niagen Bioscience to Present at Longevity Investors Conference LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference, taking place from September 14 to 17, 2026, in Gstaad, Switzerland.Niagen Bioscience CEO, Rob Fried, will participate in the Longevity Goes Ma…
View source ↗ - Newsbusinesswire.com·94d ago·Negative
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam's Club retail locations and online at www.gnc.com and www.samsclub.com. “Expand…
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $-0.04 per share
Typical surprise +100.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.01 vs $-0.01miss
- Tue, Aug 4$0.01 vs $0.01beat
- Wed, May 6$0.07 vs $0.06beat
- Wed, Mar 4$0.03 vs $0.02beat
- Tue, Nov 4$0.05 vs $0.01beat
- Wed, Aug 6$0.04 vs $0.02beat
Estimates and results for NAGE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NAGE officers and directors.
- Bought
- $46k
- Sold
- —
2 trades
0 trades
- Pamir Ozanbought
- Pamir Ozanbought
24 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NAGE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
